Boston Scientific Corporation (BSX) Analyst Ratings & Price Targets

Boston Scientific Corporation

BSX · NYSE

Analyst Consensus

Buy

25 analysts

$44

Current

$48

Low

$49

Average

$48

High

Average target implies +12.64% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 25 analysts, with a mean target of $57; low and high estimates are not available, so the target spread and named most- and least-bullish analysts cannot be established from that consensus. Wells Fargo is a clearly identifiable cautious voice, lowering its target to $48 from $50 during the week and citing cyberattack impact. The supplied sources also show higher aggregate targets on separate forecast pages, but their differing analyst counts and snapshots do not establish a comparable target range. The week’s documented revision was downward at Wells Fargo. The substantive tension is between reported FY2025 revenue and net-income growth and valuation concerns tied to cyberattack impact and an adjusted 2027 earnings forecast.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Wells Fargo	—	Not stated Maintained rating; lowered price target	$48from $50	+10.3%	Sep 23, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BTIG

C.L. KING

CANACCORD GENUI

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

EVERCORE ISI

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: BSX
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Exchange: NYSE

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Key Issues

Bullish view

The supplied evidence identifies a target cut tied to cyberattack impact, but does not quantify the effect or show that it changed the overall Buy consensus among 25 analysts.

Bearish view

Wells Fargo cut its target from $50 to $48, explicitly citing cyberattack impact, indicating a material enough concern to reduce its valuation.

Analyst Consensus

See all

Buy

25 analysts

$44

Current

$48

Low

$49

Average

$48

High

Average target implies +12.64% versus the current price.

Earnings History

BeatMissNo estimate

Boston Scientific Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers